Meeting
2014 Gastrointestinal Cancers Symposium
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
Authors
Edward Samuel James
Yale University School of Medicine, New Haven, CT
Edward Samuel James , Xiaopan Yao , Xiangyu Cong , Stacey Stein , Kristin Kaley , Carol Hahn , Charles Cha , Ronald R Salem , Howard S. Hochster , Jill Lacy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01523457
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 256)
DOI
10.1200/jco.2014.32.3_suppl.256
Abstract #
256
Poster Bd #
B29
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).
First Author: Edward Samuel James
Poster
2018 Gastrointestinal Cancers Symposium
Retrospective single center review of toxicity and efficacy of a modified FOLFIRINOX regimen in patients with locally advanced and metastatic pancreatic cancer.
First Author: Bhargavi Pulluri
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
First Author: Makoto Ueno
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka